Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
gptkb:public_company |
| gptkbp:CEO |
gptkb:Robert_I._Blum
|
| gptkbp:collaboratedWith |
gptkb:Amgen
gptkb:Astellas_Pharma |
| gptkbp:country |
gptkb:United_States
|
| gptkbp:developedBy |
small molecule therapeutics
|
| gptkbp:focusesOn |
cardiovascular diseases
muscle biology neuromuscular diseases |
| gptkbp:foundedYear |
1997
|
| gptkbp:headquartersLocation |
gptkb:South_San_Francisco,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Cytokinetics, Incorporated
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:ISIN |
gptkb:US23282W6057
|
| gptkbp:legalForm |
gptkb:Incorporated
|
| gptkbp:notableProduct |
gptkb:aficamten
gptkb:omecamtiv_mecarbil |
| gptkbp:numberOfEmployees |
approximately 200 (2023)
|
| gptkbp:researchArea |
gptkb:amyotrophic_lateral_sclerosis_(ALS)
heart failure |
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:CYTK
|
| gptkbp:tradedOn |
NASDAQ: CYTK
|
| gptkbp:website |
https://www.cytokinetics.com/
|
| gptkbp:bfsParent |
gptkb:CYTK
|
| gptkbp:bfsLayer |
7
|